Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1143)	5/30/2000 11:03:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

tuck, Medscape indeed has lots of good stuff. "Because of this finding, the vast literature on chemotherapy response rates for advanced breast cancer is more or less obsolete . . ." All we are seeing here is a natural progression that comes from gaining a better understanding of tumors. As the broad "breast cancer" gets divided up into different conditions based on different molecular-level markers, we should expect to see that existing drugs will treat specific sub-types differently. Thus we are seeing here the first small steps to individualized cancer treatment. In this particular example the marker for Herceptin susceptibility also turns out to be (negatively) significant for traditional chemo drugs. This general development is basically good for biotech, and I can't believe it had anything to do with the weakness out of ASCO. Peter